Biologics
A Deep, Multi-Dimensional Biologics Portfolio
Through a strategic development and manufacturing partnership, BioFutureRx advances a broad portfolio of biologic medicines — biosimilars, first-in-class and novel antibodies, companion diagnostics, and drug-delivery platforms — spanning oncology, immunology, and other high-need areas.
The Portfolio
Biologic medicines across the full value chain
Our partner's programs span discovery through approval, backed by an integrated platform for biosimilar and first-in-class antibody development. BioFutureRx works to bring these biologics toward new markets and patients.
- 17
- Biosimilar programs
- 18+
- Antibody programs
- 5
- Therapeutic areas
Biosimilars
A broad, CMC-ready biosimilar portfolio across oncology, immunology, and beyond — from an EU-approved program through early development.
First-in-Class Antibodies
Novel-target discovery and antibody humanization, led by a clinical-stage candidate in pancreatic cancer.
Companion Diagnostics
Diagnostic and biomarker platforms that pair with the pipeline to enable earlier, more precise treatment.
Delivery Platforms
Drug-delivery innovation — including subcutaneous and ocular routes — that extends how biologics reach patients.
Biosimilar Pipeline
Affordable, high-quality biosimilars
A CMC-ready biosimilar portfolio with regulatory-pathway expertise, advancing access to established biologic therapies. The lead program is approved in the EU, with a deep pipeline behind it.
| Molecule | Therapeutic Area | Development Stage |
|---|---|---|
| Trastuzumab biosimilar | Oncology | Approved (EU) |
| Bevacizumab biosimilar | Oncology | Pre-registration |
| Adalimumab biosimilar | Immunology | Clinical (Phase 1) |
| Denosumab biosimilar | Endocrinology | Preclinical |
| Nivolumab biosimilar | Oncology | Preclinical |
| Pembrolizumab biosimilar | Oncology | Preclinical |
| Emicizumab biosimilar | Hematology | Cell Line Development |
| Ustekinumab biosimilar | Immunology | Cell Line Development |
| Dulaglutide biosimilar | Endocrinology | Cell Line Development |
| Ocrelizumab biosimilar | Immunology | Cell Line Development |
| Vedolizumab biosimilar | Immunology | Cell Line Development |
| Pertuzumab biosimilar | Oncology | Cell Line Development |
| Dupilumab biosimilar | Dermatology | Early Development |
| Risankizumab biosimilar | Immunology | Early Development |
| Atezolizumab biosimilar | Oncology | Early Development |
| Guselkumab biosimilar | Immunology | Early Development |
| Durvalumab biosimilar | Oncology | Early Development |
Novel & First-in-Class Antibodies
Innovative antibody therapeutics
A pipeline of first-in-class, bispecific, novel-concept, and antibody-drug-conjugate programs targeting solid tumors, fibrosis, and other areas of unmet need — led by a clinical-stage candidate in pancreatic cancer.
| Category | Indication | Programs | Development Stage |
|---|---|---|---|
| First-in-Class AntibodiesNovel-target discovery and antibody humanization against validated and emerging targets. | Pancreatic cancerLead clinical candidate | 1 | Clinical (Phase 1/2a) |
| Solid tumor · Fibrosis | 1 | Preclinical | |
| Solid tumors | 3 | Discovery | |
| Infectious diseases | 2 | Discovery | |
| Bispecific AntibodiesDual-targeting formats engineered for tumor and immune-modulating indications. | Cytokine release syndrome | 1 | Cell Line Development |
| Solid tumors | 5 | Discovery | |
| Novel-Concept AntibodiesDifferentiated antibody concepts advancing through proof-of-concept studies. | Solid tumors | 4 | Proof of Concept |
| Antibody-Drug ConjugatesTargeted cytotoxic payloads for solid-tumor indications. | Solid tumor | 1 | Discovery |
Diagnostics & Platforms
Companion diagnostics and delivery innovation
Companion Diagnostics
IHC / ELISA companion-diagnostic and biomarker platform supporting early detection in pancreatic cancer.
Subcutaneous Delivery Platform
Drug-delivery system enabling subcutaneous administration of biologics, advancing in a breast-cancer setting.
Ocular Delivery Platform
Drug-delivery innovation for ocular biologic therapeutics.
A confidential partnership
These programs are advanced with an established biopharmaceutical development and manufacturing partner. Under the terms of our agreement, the partner is not named and proprietary program codes are withheld; programs are shown by molecule, indication, and stage. Full details are available to qualified counterparties under NDA.
Request the portfolio overview
For program identities, data packages, and partnering terms, contact us to begin a confidential discussion.
Confidentiality & forward-looking statements: The biologics shown are developed by a strategic partner whose identity, proprietary program designations, and reference brands are disclosed only under a non-disclosure agreement. Development stages reflect partner materials and are subject to change; programs in development are not approved in the United States. Preclinical and clinical results are not necessarily predictive of future outcomes, and there is no guarantee any program will obtain regulatory approval. Nothing on this page is an offer to sell or a solicitation of an offer to buy any security.